Home › Funds › Cormorant Asset Management, LP › ELVN
Cormorant Asset Management, LP position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
Cormorant Asset Management, LP reported holding 75,000 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$3.4M, representing 0.25% of its reported portfolio and ranking #45 among its reported holdings. Cormorant Asset Management, LP has disclosed ELVN holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's ELVN position evolved
Cormorant Asset Management, LP first disclosed a stake in ELVN in Q3 2023 at 1,216,712 shares (US$16.6M). Across 7 filings, Cormorant Asset Management, LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 75,000 shares valued at US$3.4M — a reduction of -75,000 shares quarter over quarter.. Notable position changes include a 50% trim in Q3 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.22M | $16.62M | New |
| Q4 2024 | 250.00K | $5.62M | New |
| Q1 2025 | 250.00K | $4.92M | Hold |
| Q2 2025 | 200.00K | $4.01M | Reduce |
| Q3 2025 | 200.00K | $4.09M | Hold |
| Q2 2026 | 150.00K | $7.61M | New |
| Q3 2026 | 75.00K | $3.44M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 57 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$310.6M), Polar Capital Holdings Plc (US$294.5M), Commodore Capital LP (US$150.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $310.64M · Q3 2026
- Polar Capital Holdings Plc 6.43M sh · $294.53M · Q3 2026
- Commodore Capital LP 3.27M sh · $150.13M · Q3 2026
- Vestal Point Capital, LP 3.23M sh · $147.83M · Q3 2026
- Fairmount Funds Management LLC 1.86M sh · $85.06M · Q3 2026
- Siren, L.L.C. 1.48M sh · $67.62M · Q3 2026
- Bellevue Group AG 1.47M sh · $67.34M · Q3 2026
- Logos Global Management LP 1.08M sh · $49.51M · Q3 2026
- First Light Asset Management, LLC 1.02M sh · $46.68M · Q3 2026
- Novo Holdings A/S 1.00M sh · $45.84M · Q3 2026
- First Turn Management, LLC 958.70K sh · $43.95M · Q3 2026
- SAMLYN CAPITAL, LLC 936.17K sh · $42.91M · Q3 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held ELVN?
Cormorant Asset Management, LP has disclosed ELVN holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
What is Cormorant Asset Management, LP's current position in ELVN?
As of Q3 2026, Cormorant Asset Management, LP holds 75.00K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $3.44M, representing 0.25% of its reported portfolio and ranking #45.
Has Cormorant Asset Management, LP been buying or selling ELVN?
In the latest 13F filing (Q3 2026), Cormorant Asset Management, LP reduced its position in ELVN.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Commodore Capital LP, among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.